Type 2 diabetes mellitus (T2DM) is proven to have some similarities in etiology and pathophysiology with Alzheimer’s disease (AD). In recent years, evidence also has suggested that some new drugs for diabetes, such as glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase 4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitor, have some effects on the central nervous system. These findings provide new strategy for AD treatment, that is, using these diabetes drugs for intervention of AD. In this paper, we reviewed the pathophysiological characteristics of AD, the correlation between AD and T2DM, and the application of GLP-1, DPP-4 inhibitor and SGLT2 inhibitor in the intervention of AD.